RECENT COMMENTS

Rajesh Kumar: Is it helpfull for Overian cancer patient at advance stage? Rajesh Kumar +919681303310   »Read more

Cindy: I'm not a medical professional. My mother has been diagnosed with CUP - and was treated several year [...]   »Read more

Rajesh Kumar: +919681303310.   »Read more

Rajesh Kumar: Please write your comment here   »Read more

christian: Is gabapentin has been proposed to treat peripheric neuropathy induced by chemotherapy. At low dosa [...]   »Read more

 

Article type: e-World

Keywords: Alex Jadad, Centre for Global eHealth Innovation, cancer on the internet, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Betting on e-collaboration: Interview with Dr Alex Jadad

Betting on
e-collaboration: Interview with Dr Alex Jadad

All over the world, communities are grappling in isolation with universal questions of how to prevent cancer and improve the lives of patients. But is there any reason, in this Internet age, why we should not share ideas and adapt effective strategies to local conditions. Alex Jadad, Director of the Centre for Global eHealth Innovation, believes there is not. And he is trying to prove it.

» Anna Wagstaff

To read complete article please click on the pdf icon

 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.